My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 151

    1.

    The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.

    Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H.

    Diabetes Care. 2003 Dec;26(12):3273-9.PMID: 14633813 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    3.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    4.

    Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

    Clin Ther. 2007 Nov;29(11):2374-84.PMID: 18158078 [PubMed - indexed for MEDLINE]Related articles

    5.

    Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

    Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.

    Diabetes Care. 2006 Nov;29(11):2371-7.PMID: 17065670 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

    Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

    7.

    Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

    Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.

    Diabetes Obes Metab. 2009 Jan;11(1):27-32. Epub 2007 Oct 17.PMID: 17941873 [PubMed - indexed for MEDLINE]Related articles

    8.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    10.

    Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.

    Osei K, Gaillard T, Schuster D.

    Metabolism. 2007 Jan;56(1):24-9.PMID: 17161222 [PubMed - indexed for MEDLINE]Related articles

    11.

    Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.

    Juurinen L, Kotronen A, Granér M, Yki-Järvinen H.

    J Clin Endocrinol Metab. 2008 Jan;93(1):118-24. Epub 2007 Oct 23.PMID: 17956948 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Rosiglitazone RECORD study: glucose control outcomes at 18 months.

    Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P; RECORD Study Group.

    Diabet Med. 2007 Jun;24(6):626-34.PMID: 17517066 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

    Fonseca V, Rosenstock J, Patwardhan R, Salzman A.

    JAMA. 2000 Apr 5;283(13):1695-702. Erratum in: JAMA 2000 Sep 20;284(11):1384. PMID: 10755495 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.

    Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E.

    Diabetes Care. 2004 Jun;27(6):1349-57.PMID: 15161787 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

    Yki-Järvinen H, Dressler A, Ziemen M; HOE 901/300s Study Group.

    Diabetes Care. 2000 Aug;23(8):1130-6.PMID: 10937510 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure.

    Altuntas Y, Ozen B, Ozturk B, Sengul A, Ucak S, Ersoy O, Karul S.

    Diabetes Obes Metab. 2003 Nov;5(6):371-8.PMID: 14617222 [PubMed - indexed for MEDLINE]Related articles

    17.

    Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.

    Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, Tulokas T, Hulme S, Hardy K, McNulty S, Hänninen J, Levänen H, Lahdenperä S, Lehtonen R, Ryysy L.

    Diabetologia. 2006 Mar;49(3):442-51. Epub 2006 Feb 3.PMID: 16456680 [PubMed - indexed for MEDLINE]Related articles

    18.

    Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.

    Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group.

    Clin Ther. 2004 Dec;26(12):2034-44. Erratum in: Clin Ther. 2005 Jul;27(7):1112. PMID: 15823767 [PubMed - indexed for MEDLINE]Related articles

    19.

    Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

    Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.

    Clin Ther. 2005 Oct;27(10):1548-61.PMID: 16330291 [PubMed - indexed for MEDLINE]Related articles

    20.

    Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.

    Yilmaz H, Gursoy A, Sahin M, Guvener Demirag N.

    Acta Diabetol. 2007 Dec;44(4):187-92. Epub 2007 Aug 29.PMID: 17726570 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity